CLAIMS

1. Use of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in the manufacture of a medicament for the adjuvant treatment after tumour resection of a patient with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC) , wherein the EGFR TKI is either a second-generation or third-generation EGFR TKI,

wherein the patient has been classified with stage II or IIIA EGFRm NSCLC,

wherein the patient has received adjuvant chemotherapy,


wherein the EGFRm NSCLC comprises activating mutations in EGFR selected from exon 19 deletions or exon 21 L858R substitution mutations,

wherein the adjuvant EGFR TKI treatment provides improved disease free survival (DFS).

2. The use according to claim 1, wherein the adjuvant EGFR TKI treatment provides a probability of DFS of 85% to 95% at about 24 months.

3. The use according to claim 1 or 2, wherein the EGFR TKI is a third-generation EGFR TKI.

4. The use according to any one of claims 1 to 3, wherein the EGFR TKI is a third-generation EGFR TKI of Formula (I):



(I)

wherein:

G is selected from 4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl, indol-3-yl, indazol-1-yl, 3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-10-yl, 6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl, 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl, pyrrolo[3,2-b]pyridin-3-yl and pyrazolo[1,5-*a*]pyridin-3-yl;

R^1 is selected from hydrogen, fluoro, chloro, methyl and cyano;

R^2 is selected from methoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy and methyl;

R^3 is selected from (3*R*)-3-(dimethylamino)pyrrolidin-1-yl, (3*S*)-3-(dimethyl-amino)pyrrolidin-1-yl, 3-(dimethylamino)azetidin-1-yl, [2-(dimethylamino)ethyl]-(methyl)amino, [2-

(methylamino)ethyl](methyl)amino, 2-(dimethylamino)ethoxy, 2-(methylamino)ethoxy, 5-methyl-2,5-diazaspiro[3.4]oct-2-yl, (3a*R*,6a*R*)-5-methylhexa-hydro-pyrrolo[3,4-*b*]pyrrol-1(2*H*)-yl, 1-methyl-1,2,3,6-tetrahydropyridin-4-yl, 4-methylpiperizin-1-yl, 4-[2-(dimethylamino)-2-oxoethyl]piperazin-1-yl, methyl[2-(4-methylpiperazin-1-yl)ethyl]amino, methyl[2-(morpholin-4-yl)ethyl]amino, 1-amino-1,2,3,6-tetrahydropyridin-4-yl and 4-[(2*S*)-2-aminopropanoyl]piperazin-1-yl;

R^4 is selected from hydrogen, 1-piperidinomethyl and N,N-dimethylaminomethyl;

R^5 is independently selected from methyl, ethyl, propyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro and cyclopropyl;

X is CH or N; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

5. The use according to any one of claims 1 to 4, wherein the third-generation EGFR TKI is selected from the group consisting of osimertinib or a pharmaceutically acceptable salt thereof, AZD3759 or a pharmaceutically acceptable salt thereof, lazertinib or a pharmaceutically acceptable salt thereof, abivertinib or a pharmaceutically acceptable salt thereof, alflutinib or a pharmaceutically acceptable salt thereof, CK-101 or a pharmaceutically acceptable salt thereof, HS-10296 or a pharmaceutically acceptable salt thereof and BPI-7711 or a pharmaceutically acceptable salt thereof.

6. The use according to any one of claims 1 to 5, wherein the third generation EGFR TKI is osimertinib, or a pharmaceutically acceptable salt thereof.

7. The use according to claim 6, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is to be administered once-daily.

8. The use according to either claim 6 or claim 7, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is to be administered in tablet form.

9. The use according to any one of claims 6 to 8, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is osimertinib mesylate.

10. The use according to claim 1 or 2, wherein the EGFR TKI is a second-generation EGFR TKI selected from afatinib and dacomitinib.